Drug recall · June 24, 2026
Alyacen 7/7/7 recall
Why: Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Alyacen 7/7/7, Norethindrone and Ethinyl Estradiol Tablets USP, 0.5mg/0.035mg, 0.75mg/0.035mg, 1 mg/0.0.35mg, 3 Blister Cards each containing 28 tablets, 28 day regimen, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd., Colvale-Bardez, Goa 403 513, India, Manufactured for: Glenmark Pharmaceuticals Inc., Mahwah, NJ 07430, NDC 68462-556-29
- Lots / codes
Lot #: 20240411, Exp: 6/30/2026; 20250252, Exp: 3/31/2027
- Company
- Glenmark Pharmaceuticals Inc., USA, Elmwood Park, NJ
- Distribution
- USA Nationwide.
- Initiated
- May 27, 2026 · Voluntary: Firm initiated
- Classified
- June 12, 2026
- Reported
- June 24, 2026
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ethinyl estradiol / norethindrone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.